Key Takeaways from Panel Discussion at WEF Davos – “The Race for Compassionate Use”

Earlier this month, WEP Clinical had the incredible opportunity to participate in the prestigious World Economic Forum (WEF) Davos event, as a proud sponsor of the Partner for Patient conference, HEAL - Health Equity Action [...]

By |2025-12-01T19:01:58+00:00January 28th, 2025|WEP Insights|

Why Choosing a Small Contract Research Organization (CRO) Can Elevate Your Clinical Trials

In today’s fast-paced pharmaceutical landscape, selecting the right partner for your clinical trials is crucial. Here are some compelling benefits of opting for a small CRO: Personalized AttentionSmall CROs often provide tailored solutions and dedicated [...]

By |2025-12-01T19:04:44+00:00October 23rd, 2024|WEP Insights|

Transition Management in Post-Trial and Expanded Access Programs: Navigating Change with Precision

In the world of pharmaceutical development, Expanded Access Programs (EAPs) and Post-Trial Access (PTA) initiatives play a crucial role in delivering life-saving therapies to patients in need. These programs are essential for providing access to [...]

By |2025-12-01T19:03:25+00:00October 8th, 2024|WEP Insights|

Enhancing Biotech Innovation: The Power of WEP Clinical’s Value-Added CRO Services

Selecting the right CRO is crucial for biotech companies, as it can significantly impact the success of clinical trials and, ultimately, the development of new therapies. There are key reasons why value-added services are important [...]

By |2025-11-27T12:24:45+00:00September 12th, 2024|WEP Insights|

When is the Right Time to Consider an FDA Special Designation for Your Rare Disease Asset?

Navigating the regulatory landscape for rare disease treatments can be challenging. One critical decision is determining the right time to seek an FDA special designation, such as Orphan Drug, Fast Track, Breakthrough Therapy, or Rare [...]

By |2025-11-27T12:25:36+00:00August 20th, 2024|WEP Insights|